REGULATORY CHALLENGES AND LANDSCAPES OF MONOCLONAL ANTIBODY REGISTRATION: GLOBAL OUTLOOK
DOI:
https://doi.org/10.22159/ijpps.2024v16i5.50723Abstract
Objective: This review aims to illuminate the unprecedented growth and versatile therapeutic landscape of monoclonal antibody (mAb) products, highlighting their significant impact on diverse medical fields such as oncology, septicemia treatment, infection management, and substance abuse disorder interventions. This review outlines the challenges associated with the development, manufacturing, and regulatory approval of monoclonal antibodies, emphasizing the need for diligent attention to overcome these complexities. The review comprehensively examines the historical evolution and therapeutic applications of monoclonal antibodies, emphasizing their potent and versatile characteristics that have enabled successful interventions in challenging regulatory approvals. It delves into the critical considerations in manufacturing, regulatory navigation, and the strategic integration of expedited approval pathways, providing a holistic understanding of the intricate terrain of innovation, clinical translation, and impactful patient care in the realm of monoclonal antibody products. Monoclonal antibodies have significantly advanced medical treatment in various domains, revolutionizing cancer therapy, offering new avenues for septicemia management, augmenting the arsenal against infections, and opening novel pathways for addressing substance abuse disorders. Their development and regulatory approval are associated with challenges of scientific innovation, manufacturing, and regulatory compliance. Despite the challenges, monoclonal antibodies have demonstrated remarkable potential in addressing complex medical conditions. The review serves as a compass, guiding researchers, clinicians, and regulatory authorities through the intricate terrain of monoclonal antibody innovation and clinical translation. It emphasizes the need for diligent attention to overcome the complexities associated with their development and regulatory approval while highlighting their significant impact on advancing patient care.
Downloads
References
WHO Guideline for the safe production and quality control of monoclonal antibodies for use in humans. Available from: https://cdn.who.int/media/docs/default-source/BioLogicals/mabs-manufacture-guideline-draft-for-1st-public-comment.pdf. [Last accessed on 19 Aug 2023]
Weinberg WC, Frazier Jessen MR, Wu WJ, Weir A, Hartsough M, Keegan P. Development and regulation of monoclonal antibody products: challenges and opportunities. Cancer Metastasis Rev. 2005 Dec;24(4):569-84. doi: 10.1007/s10555-005-6196-y, PMID 16408162.
Lynch CM, Grewal IS. Preclinical safety evaluation of monoclonal antibodies. Handb Exp Pharmacol. 2008;(181):19-44. doi: 10.1007/978-3-540-73259-4_2, PMID 18071940.
Quinteros DA, Bermudez JM, Ravetti S, Cid A, Allemandi DA, Palma SD. Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery. Nanostruct Drug Deliv. 2017 Jan 1;807-33. doi: 10.1016/B978-0-323-46143-6.00025-7
Lyu X, Zhao Q, Hui J, Wang T, Lin M, Wang K. The global landscape of approved antibody therapies. Antib Ther. 2022 Oct 1;5(4):233-57. doi: 10.1093/abt/tbac021, PMID 36213257.
Liu JKH. The history of monoclonal antibody development-progress, remaining challenges and future innovations. Ann Med Surg (Lond). 2014 Dec 1;3(4):113-6. doi: 10.1016/j.amsu.2014.09.001, PMID 25568796.
The history of monoclonal antibody development–Progress, remaining challenges and future innovations-PMC. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284445. [Last accessed on 19 Aug 2023]
Weinberg WC, Frazier Jessen MR, Wu WJ, Weir A, Hartsough M, Keegan P. Development and regulation of monoclonal antibody products: challenges and opportunities. Cancer Metastasis Rev. 2005 Dec;24(4):569-84. doi: 10.1007/s10555-005-6196-y, PMID 16408162.
ICH Official web site. ICH. Available from: https://www.ich.org/page/quality-guidelines. [Last accessed on 18 Mar 2024]
WHO Guideline on the nonclinical and clinical evaluation of monoclonal antibodies and related biological products intended for the prevention or treatment of human infectious diseases. Available from: https://cdn.who.int/media/docs/default-source/BioLogicals/call-for-comments/mab-clinical-guideline-final-for-posting-19Aug2022_.pdf?sfvrsn=62728b75_1 [Last accessed on 19 Aug 2023]
Tarantino P, Ricciuti B, Pradhan SM, Tolaney SM. Optimizing the safety of antibody–drug conjugates for patients with solid tumours. Nat Rev Clin Oncol. 2023 Aug 1;20(8):558-76. doi: 10.1038/s41571-023-00783-w, PMID 37296177.
Lyu X, Zhao Q, Hui J, Wang T, Lin M, Wang K. The global landscape of approved antibody therapies. Antib Ther. 2022 Oct 1;5(4):233-57. doi: 10.1093/abt/tbac021, PMID 36213257.
Hasan MM, Laws M, Jin P, Rahman KM. Factors influencing the choice of monoclonal antibodies for antibody–drug conjugates. Drug Discov Today. 2022 Jan 1;27(1):354-61. doi: 10.1016/j.drudis.2021.09.015, PMID 34597756.
Estanqueiro M, Amaral MH, Conceicao J, Manuel J, Lobo S. Evolution of liposomal carriers intended to anticancer drug delivery: an overview. Int J Curr Pharm Res. 2015 Oct 17:26-33.
Quinteros DA, Bermudez JM, Ravetti S, Cid A, Allemandi DA, Palma SD. Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery. Nanostruct Drug Deliv. 2017 Jan 1;807-33.
Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery-PMC. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151974. [Last accessed on 19 Aug 2023]
Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies. Am J Med Sci. 2002;324(1):14-30. doi: 10.1097/00000441-200207000-00004, PMID 12120821.
Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. doi: 10.1186/s12929-019-0592-z, PMID 31894001.
Overview of therapeutic monoclonal antibodies-UpToDate. Available from: https://www.uptodate.com/contents/overview-of-therapeutic-monoclonal-antibodies. [Last accessed on 19 Aug 2023]
Chen YH, Wu KL, Tsai HM, Chen CH. Treatment of methamphetamine abuse: an antibody-based immunotherapy approach. J Food Drug Anal. 2013 Dec 1;21(4):S82-6. doi: 10.1016/j.jfda.2013.09.040, PMID 26334109.
Hossain CM, Maitra S, Lyle N, Gera M, Paul S, Dutta D. Immunotherapy as novel treatment of lung cancer: a systematic review. Asian J Pharm Clin Res. 2022 Dec 7:9-17. doi: 10.22159/ajpcr.2022.v15i12.46133.
Monoclonal antibody drugs for cancer: how they work-Mayo Clinic. Available from: https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/monoclonal-antibody/art-20047808. [Last accessed on 19 Aug 2023]
Goldstein RH, Walensky RP. The challenges ahead with monoclonal antibodies: from authorization to access. JAMA. 2020 Dec 1;324(21):2151-2. doi: 10.1001/jama.2020.21872, PMID 33175110.
Sifniotis V, Cruz E, Eroglu B, Kayser V. Current advancements in addressing key challenges of therapeutic antibody design, manufacture, and formulation. Antibodies (Basel). 2019;8(2). doi: 10.3390/antib8020036, PMID 31544842.
Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. doi: 10.1186/s12929-019-0592-z, PMID 31894001.
Liu JKH. The history of monoclonal antibody development – Progress, remaining challenges and future innovations. Ann Med Surg (Lond). 2014 Dec 1;3(4):113-6. doi: 10.1016/j.amsu.2014.09.001, PMID 25568796.
Geng X, Kong X, Hu H, Chen J, Yang F, Liang H. Research and development of therapeutic mAbs: an analysis based on pipeline projects. Hum Vaccin Immunother. 2015 Jan 1;11(12):2769-76. doi: 10.1080/21645515.2015.1074362, PMID 26211701.
Li J, Zhu Z. Research and development of next generation of antibody-based therapeutics. Acta Pharmacol Sin. 2010;31(9):1198-207. doi: 10.1038/aps.2010.120, PMID 20694021.
Gutierrez L, Cauchon NS, Christian TR, Giffin MJ, Abernathy MJ. The confluence of innovation in therapeutics and regulation: recent CMC considerations. J Pharm Sci. 2020 Dec 1;109(12):3524-34. doi: 10.1016/j.xphs.2020.09.025, PMID 32971125.
Schneider CK. Monoclonal antibodies-regulatory challenges. Curr Pharm Biotechnol. 2008 Dec 6;9(6):431-8. doi: 10.2174/138920108786786394, PMID 19075683.
Qing Zhou, Marjorie Shapiro. Regulatory considerations for the development of novel antibody-related products. Am Pharm Rev Rev Am Pharm Bus Technol; 2016. Available from: https://www.americanpharmaceuticalreview.com/Featured-Articles/185969-Regulatory-Considerations-for-the-Development-of-Novel-Antibody-Related-Products.
George B. Regulatory framework and challenges in developing biosimilar monoclonal antibodies and related biological products. Int J Pharm. 2012 Jan 1;5(3):1765-74. doi: 10.37285/ijpsn.2012.5.3.3/index.php/ijpsn/article/view/582.
New drug application (NDA). FDA. Available from: https://www.fda.gov/drugs/types-applications/new-drug-application-nda.
Biologics license applications (BLA) process (CBER). FDA. Available from: https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biologics-license-applications-bla-process-cber. [Last accessed on 19 Aug 2023]
Therapeutic biologics applications (BLA). FDA. Available from: https://www.fda.gov/drugs/types-applications/therapeutic-biologics-applications-bla [Last accessed on 19 Aug 2023]
European Medicines Agency. Pre-authorisation procedural advice for users of the centralised procedure. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/EuropeanMedicinesAgency-pre-authorisation-procedural-advice-users-centralised-procedure_en-0.pdf [Last accessed on 17 Aug 2023]
The centralised procedure at EMA. Available from: https://www.ema.europa.eu/en/documents/presentation/presentation-centralised-procedure-European-medicines-agency_en.pdf [Last accessed on 19 Aug 2023]
Comparison of marketing authorization procedures for biotechnological products in the European Union (centralized procedure) and in Japan (J-NDA). Available from: https://www.dgra.de/media/pdf/studium/masterthesis/master_metzner_b.pdf [Last accessed on 19 Aug 2023]
The drug approval process in Japan (IND, NDA, Generics, Biologics). Available from: https://credevo.com/articles/2020/04/15/the-drug-approval-process-in-japan. [Last accessed on 19 Aug 2023]
Fast track, breakthrough therapy, accelerated approval, priority review. FDA. Available from: https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review [Last accessed on 19 Aug 2023]
FDA’s expedited approval mechanisms for new drug products-PMC. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326266 [Last accessed on 19 Aug 2023]
Kepplinger EE. FDA’s expedited approval mechanisms for new drug products. Biotechnol Law Rep. 2015 Feb 2;34(1):15-37. doi: 10.1089/blr.2015.9999, PMID 25713472.
Accelerated assessment. European Medicines Agency. Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/accelerated-assessment [Last accessed on 19 Aug 2023]
Conditional marketing authorisation. European Medicines Agency. Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/conditional-marketing-authorisation [Last accessed on 19 Aug 2023]
Tanaka M, Idei M, Sakaguchi H, Kato R, Sato D, Sawanobori K. Evolving landscape of new drug approval in Japan and lags from international birth dates: retrospective regulatory analysis. Clin Pharmacol Ther. 2021 May 1;109(5):1265-73. doi: 10.1002/cpt.2080, PMID 33048367.
Tanaka M, Idei M, Sakaguchi H, Kato R, Sato D, Sawanobori K. Achievements and challenges of the Sakigake designation system in Japan. Br J Clin Pharmacol. 2021 Oct 1;87(10):4027-35. doi: 10.1111/bcp.14807, PMID 33694268.
Achievements and challenges of the Sakigake designation system in Japan-Tanaka-2021-British. J Clin Pharmacol-Wiley Online. Available from: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.14807
Strategy of SAKIGAKE as a package. Available from: https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/dl/140729-01-02.pdf [Last accessed on 19 Aug 2023]
Nagai S. Flexible and expedited regulatory review processes for innovative medicines and regenerative medical products in the US, the EU, and Japan. Int J Mol Sci. 2019 Aug 1;20(15). doi: 10.3390/ijms20153801, PMID 31382625.
Tanaka M, Miyazawa H, Terashima R, Ikuma M. Conditional early approval for new drug applications in Japan: current and emerging issues. Clin Transl Sci. 2023 Aug 1;16(8):1289-93. doi: 10.1111/cts.13536, PMID 37161871.
Published
How to Cite
Issue
Section
Copyright (c) 2024 SURJONARAYAN MOTILAL, SANGITA MISHRA, M. ARJUN, M. P. VENKATESH
This work is licensed under a Creative Commons Attribution 4.0 International License.
